Acorda third one fourth GAAP net gain increases to $18 treatments .9 million Acorda Therapeutics, Inc. today announced its economic results for the third quarter ended September 30, 2011. Persistence and compliance rates among sufferers who react to AMPYRA are high. Persistence and compliance rates among patients who respond to AMPYRA are high. This will become an important contributor to the long-term growth of the brand, stated Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. In addition, independent market research indicates our marketing campaigns, which highlight the advantages of AMPYRA in people with early-stage walking impairment, are resonating with prescribers.
Actavis announces acquisition of Silom Medical for $100 million Actavis plc , a respected global specialty pharmaceutical company today announced that it has acquired Silom Medical Business, a privately held generic pharmaceutical company focused on marketing and developing therapies in Thailand, for about $100 million in cash. The acquisition of Silom Medical immediately elevates Actavis right into a top-five placement in the Thai generic pharmaceutical market, with leading positions in the respiratory and ophthalmic therapeutic categories and a solid cardiovascular franchise.’ Related StoriesCamels in Kenya contaminated by MERS virus, new study findsLuminex's NxTAG Respiratory Pathogen Panel receives CE-IVD markingAfter acute myocardial infarction, respiratory infection connected with increased threat of mortality Actavis currently markets approximately a dozen products through regional distributors in Thailand, and has 9 additional products under sign up approximately.